title: Maturation of NK1 receptor involvement in the nociceptive response to formalin.
abstract: Administration of NK1 antagonists in adult animals attenuates the nociceptive response in the formalin test, indicating that the neurokinins and the NK1 receptor play a role in mediating this pain response. The number and distribution of NK1 receptors change dramatically during development, and the age at which they become involved in pain processing is not known. We examined the role of NK1 receptors in the formalin model in rats ranging in age between 3- and 21-days old. An NK1 antagonist, CP99,994, and its less active enantiomer CP100,263 were administered to the spinal cord (intrathecal), systemically (subcutaneous), or locally (intraplantar). Intrathecal administration of CP99,994, but not CP100,263, attenuated pain behaviors in the second phase of the formalin response in 14-day and 21-day old rats, but did not alter the pain response in 3-day or 10-day old rats. CP99,994 also reduced the expression of the c-fos protein in the superficial dorsal horn of 21-day old rats. Systemic and intraplantar injection of either CP99,994 or CP100,263 reduced the pain response to formalin in 3-day and 21-day old rats, suggesting a non-NK1 mediated mechanism of action. These results indicate that, within the spinal cord, NK1 receptors start to play a role in the pain response to formalin between 10 and 21 days. Moreover, analgesia induced by systemic or local injection of NK1 antagonists involves mechanisms other than, or in addition to, the NK1 receptor.
authors.affiliation: Department of Psychology, Hunter College, New York, NY 10021, USA. taking@shiva.hunter.cuny.edu
authors.forename: T E
authors.initials: TE
authors.lastname: King
authors.forename: J
authors.initials: J
authors.lastname: Cheng
authors.forename: S
authors.initials: S
authors.lastname: Wang
authors.forename: G A
authors.initials: GA
authors.lastname: Barr
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D005557:Formaldehyde / Q000494:pharmacology*; D006614:Hindlimb; D007267:Injections; D007278:Injections, Spinal; D007279:Injections, Subcutaneous; D064729:Neurokinin-1 Receptor Antagonists; D009619:Nociceptors / Q000187:drug effects* / Q000502:physiology; D010880:Piperidines / Q000008:administration & dosage / Q000494:pharmacology; D051381:Rats; D020318:Rats, Long-Evans; D018040:Receptors, Neurokinin-1 / Q000502:physiology*; D013237:Stereoisomerism
chemical_list: D064729:Neurokinin-1 Receptor Antagonists; D010880:Piperidines; D018040:Receptors, Neurokinin-1; C080755:3-(2-methoxybenzylamino)-2-phenylpiperidine; D005557:Formaldehyde